['atopic dermatitis']
['dupilumab', 'placebo (for dupilumab)']

        Key Inclusion Criteria:

          1. Chronic AD that had been present for at least 3 years before the screening visit;

          2. Documented recent history (within 6 months before the screening visit) of inadequate
             response to a sufficient course of out-patient treatment with topical AD
             medication(s).

        Key Exclusion Criteria:

          1. Participation in a prior Dupilumab clinical trial;

          2. Important side effects of topical medication (e.g. intolerance to treatment,
             hypersensitivity reactions, significant skin atrophy, systemic effects), as assessed
             by the investigator or treating physician;

          3. Having used any of the following treatments within 4 weeks before the baseline visit,
             or any condition that, in the opinion of the investigator, was likely to require such
             treatment(s) during the first 2 weeks of study treatment:

               1. Immunosuppressive/immunomodulating drugs (e.g, systemic steroids, cyclosporine,
                  mycophenolate-mofetil, Janus kinase inhibitors, interferon-gamma [IFN-γ],
                  azathioprine, methotrexate, etc.);

               2. Phototherapy for AD;

          4. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit;

          5. History of human immunodeficiency virus (HIV) infection or positive HIV serology at
             screening;

          6. Positive hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or
             hepatitis C antibody at the screening visit;

          7. Active or acute infection requiring systemic treatment within 2 weeks before baseline
             visit;

          8. Known or suspected history of immunosuppression;

          9. Pregnant or breastfeeding women, or planning to become pregnant or breastfeed during
             the participant's participation in this study.

        Note: The eligibility criteria listed above is not intended to contain all considerations
        relevant to a participant's potential participation in a clinical trial therefore not all
        inclusion/ exclusion criteria are listed.
      